A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Children With Attention Deficit-Hyperactivity Disorder (ADHD).

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Children With Attention Deficit-Hyperactivity Disorder (ADHD).

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs Pozanicline (Primary) ; Atomoxetine
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 22 Aug 2011 Additional lead trial investigator identified as reported by ClincalTrials.gov.
    • 15 Dec 2008 Planned number of patients changed from 270 to 278 as reported by ClinicalTrials.gov.
    • 15 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top